MedMatrix Rx
Daily 340B Morning Briefing for Executives
Johnson & Johnson’s new claims data requirement for 340B pricing takes effect tomorrow, impacting all covered entities. Meanwhile, Scripps Health anticipates a $100 million annual revenue impact from HR 1 due to Medi-Cal changes. NASP and hospital groups have submitted comments on CMS’s proposed 340B payment changes, urging adjustments to preserve patient access and financial stability. Ongoing litigation continues to shape the 340B landscape, with notable cases involving major health systems and pharmaceutical companies.
EXECUTIVE SUMMARY
01
Johnson & Johnson mandates claims data for 340B discounts.
Starting September 15, J&J requires 340B entities to submit claims data or face pricing suspension. Compliance restores pricing within 10 days.
Starting September 15, J&J requires 340B entities to submit claims data or face pricing suspension. Compliance restores pricing within 10 days.
Source: Healthcare Dive
02
Scripps Health projects $100M revenue loss from HR 1.
Scripps Health estimates HR 1 will reduce its net revenue by up to $100 million annually, driven by Medi-Cal enrollment cuts and provider fee limits.
Scripps Health estimates HR 1 will reduce its net revenue by up to $100 million annually, driven by Medi-Cal enrollment cuts and provider fee limits.
Source: Becker’s Hospital Review
03
NASP comments on CMS’s 340B payment changes.
NASP submitted comments to CMS on proposed changes to Medicare reimbursement for 340B drugs. The comments included implications for specialty pharmacy services.
NASP submitted comments to CMS on proposed changes to Medicare reimbursement for 340B drugs. The comments included implications for specialty pharmacy services.
Source: NASP
04
Milwaukee hospital sues CVS over $18M 340B diversion.
Froedtert Memorial Lutheran Hospital alleges CVS diverted $18 million in 340B savings, filing suit in U.S. District Court for the Eastern District of Wisconsin.
Froedtert Memorial Lutheran Hospital alleges CVS diverted $18 million in 340B savings, filing suit in U.S. District Court for the Eastern District of Wisconsin.
Source: Becker’s Hospital Review
05
Hospital groups urge CMS to revise 2027 outpatient rule.
AHA, AAMC, and AMGA submitted comments urging CMS to withdraw or modify key provisions of the 2027 outpatient payment rule affecting 340B drug payments.
AHA, AAMC, and AMGA submitted comments urging CMS to withdraw or modify key provisions of the 2027 outpatient payment rule affecting 340B drug payments.
Source: Becker’s Hospital Review
06
HRSA to launch 340B Rebate Model Pilot Program.
HRSA’s revised 340B Rebate Model Pilot Program will start January 1, 2027, focusing on MFP drugs, representing a small fraction of 340B sales.
HRSA’s revised 340B Rebate Model Pilot Program will start January 1, 2027, focusing on MFP drugs, representing a small fraction of 340B sales.
Source: Drug Channels
07
AHA warns CMS on 340B history repetition.
AHA urges CMS not to finalize proposals accelerating Medicare payment clawbacks and cutting 340B reimbursement, citing significant hospital cost impacts.
AHA urges CMS not to finalize proposals accelerating Medicare payment clawbacks and cutting 340B reimbursement, citing significant hospital cost impacts.
Source: Becker’s Hospital Review
08
AbbVie 340B lawsuit sees new interventions.
A federal judge allowed hospital and health center groups to intervene in AbbVie’s lawsuit challenging 340B contract pharmacy restrictions.
A federal judge allowed hospital and health center groups to intervene in AbbVie’s lawsuit challenging 340B contract pharmacy restrictions.
Source: Becker’s Hospital Review
09
AAMC and AHA push for 340B provision rewrites.
AAMC and AHA filed comments targeting CMS’s Medicare Drug Price Negotiation Program rule and Sen. Cassidy’s 340B discussion draft, seeking key changes.
AAMC and AHA filed comments targeting CMS’s Medicare Drug Price Negotiation Program rule and Sen. Cassidy’s 340B discussion draft, seeking key changes.
Source: Becker’s Hospital Review
10
Elevance Health sues Senderra Rx Partners in 340B dispute.
Elevance Health filed a lawsuit against Senderra Rx Partners in the Middle District of Florida over 340B program issues.
Elevance Health filed a lawsuit against Senderra Rx Partners in the Middle District of Florida over 340B program issues.
Source: CourtListener — M.D. Fla.
EXECUTIVE SUMMARY — KEY TAKEAWAYS
Most important 340B implication. Johnson & Johnson’s new claims data requirement for 340B pricing reflects a growing trend among manufacturers to impose stricter reporting standards on covered entities. This move could lead to increased administrative burdens for hospitals and clinics, potentially affecting their ability to participate in the 340B program. As more manufacturers adopt similar requirements, covered entities may face challenges in maintaining compliance and accessing discounted drug pricing, impacting their financial stability and patient care capabilities.
Emerging risks.
- J&J’s claims data requirement could disrupt 340B pricing access for non-compliant entities.
- HR 1’s impact on Medi-Cal could significantly reduce Scripps Health’s revenue.
- CMS’s proposed 340B payment cuts may strain hospital finances further.
- Litigation outcomes could alter 340B program rules and reimbursement practices.
- Non-compliance with new manufacturer requirements may lead to pricing suspensions.
Emerging opportunities.
- Entities can use claims data submission to ensure continued 340B pricing access.
- Engagement in CMS comment periods allows stakeholders to influence policy outcomes.
- Hospitals can prepare for HR 1 impacts by adjusting financial strategies.
- Participation in HRSA’s 340B Rebate Model Pilot offers insights into new pricing models.
- Intervening in ongoing litigation provides a platform to advocate for favorable 340B policies.
Key actions for providers.
- Submit required claims data to J&J to avoid 340B pricing suspension.
- Review and adjust financial forecasts in light of HR 1’s potential impacts.
- Engage with CMS on proposed 340B payment changes during comment periods.
- Monitor ongoing litigation for developments that may affect 340B program participation.
- Prepare for HRSA’s 340B Rebate Model Pilot Program launch in 2027.
TOP STORIES
J&J mandates claims data for 340B pricing.
Healthcare Dive · September 14, 2026
- J&J requires 340B entities to submit claims data starting September 15.
- Non-compliance results in pricing suspension, restored within 10 days post-compliance.
- Applies to all covered entities regardless of drug dispensing location.
Scripps Health projects $100M revenue loss from HR 1.
Becker’s Hospital Review · September 9, 2026
- HR 1 could cut Scripps Health’s revenue by $100 million annually.
- Medi-Cal enrollment reductions and provider fee limits drive the estimate.
- Statewide impact on California estimated at $9.5 billion annually.
NASP comments on CMS’s 340B payment changes.
NASP · September 1, 2026
- NASP submitted comments on CMS’s proposed 340B payment changes.
- Comments address reimbursement methodology and specialty pharmacy implications.
- Focus on preserving patient access and operational considerations.
FEDERAL POLICY & REGULATORY DEVELOPMENTS
Milwaukee hospital sues CVS over $18M 340B diversion.
Becker’s Hospital Review · August 31, 2026
- Froedtert Hospital alleges CVS diverted $18 million in 340B savings.
- Lawsuit filed in U.S. District Court for the Eastern District of Wisconsin.
- Claims involve CaremarkPCS, CVS Specialty, and WellPartner.
Hospital groups urge CMS to revise 2027 outpatient rule.
Becker’s Hospital Review · August 31, 2026
- AHA, AAMC, and AMGA submitted comments against CMS’s 2027 rule.
- Groups oppose 340B payment cuts and site-neutral payment expansion.
- Comments highlight financial pressures and prior authorization concerns.
HRSA to launch 340B Rebate Model Pilot Program.
Drug Channels · August 25, 2026
- HRSA’s 340B Rebate Model Pilot starts January 1, 2027.
- Focuses on MFP drugs, representing less than 5.5% of 2025 340B sales.
- Pilot aims to test new pricing models amid MFP and 340B conflicts.
340B PROGRAM DEVELOPMENTS
Johnson & Johnson imposes claims data requirement for 340B.
Becker’s Hospital Review · September 11, 2026
- J&J requires claims data submission for 340B pricing from September 15.
- Non-compliant entities face pricing suspension after two notices.
- Policy affects all covered entities, regardless of drug administration location.
STATE DEVELOPMENTS
Washington — Prohibition on Medicaid Billing by 340B Contract Pharmacies
Washington State Health Care Authority · September 2026
- Washington State Health Care Authority prohibits contract pharmacies from billing Medicaid for drugs purchased at 340B prices.
- This applies to both fee-for-service and managed care claims.
- Covered entities must bill the state at Actual Acquisition Cost for fee-for-service claims.
- Source: Washington State Health Care Authority
- Date: September 2026
LITIGATION & ENFORCEMENT WATCH
| Court | Matter | Date |
|---|---|---|
| M.D. Fla. | The Elevance Health Companies, Inc. v. Senderra Rx Partners, LLC [source] | September 4, 2026 |
| D.D.C. | COREWELL HEALTH WILLIAM BEAUMONT UNIVERSITY HOSPITAL v. KENNEDY [source] | September 3, 2026 |
| D. Maryland | State of New York v. U.S. Department of Health and Human Services [source] | August 27, 2026 |
| E.D. Wis. | Froedtert Memorial Lutheran Hospital Inc v. CVS Health Corporation [source] | August 20, 2026 |
MANUFACTURER WATCH
| Manufacturer | Action | Date |
|---|---|---|
| Johnson & Johnson | Requires 340B entities to submit claims data for pricing access. [source] | September 14, 2026 |
WHAT TO WATCH NEXT
- J&J’s claims data requirement for 340B pricing takes effect September 15. [source]
- HRSA’s 340B Rebate Model Pilot Program launches January 1, 2027. [source]
- CMS to review comments on 2027 outpatient payment rule proposals. [source]
- Monitor ongoing litigation involving 340B program disputes. [source]
End of briefing.
This briefing is provided for informational purposes only and does not constitute legal, regulatory, financial, or compliance advice. Automated summarization may contain errors or omissions, and source materials may change after publication. Recipients should independently verify all information against the cited primary sources before relying on it.
© 2026 MedMatrix Rx. All rights reserved.